Introduction {#Sec1}
============

Globally an estimated 415 million people have diabetes, and this is projected to increase to 642 million by 2040 \[[@CR1]\]. According to the estimates of the Serbian Institute of Public Health, diabetes affects 12.4% of the adult population in Serbia \[[@CR2]\]. Diabetes is a chronic metabolic disorder characterised by high blood sugar levels (hyperglycaemia) and is a leading cause of blindness, end-stage renal failure, heart attack/stroke, non-traumatic amputation and depression \[[@CR1]\]. Diabetes and related complications are chief causes of death in most countries, and according to the International Diabetes Federation (IDF), there were an estimated 10,616 diabetes-related deaths in the 20--79 age group in Serbia in 2015 \[[@CR1]\].

The treatment of diabetes has a substantial economic impact on national healthcare systems. The treatment of diabetes-related chronic complications accounts for the largest proportion of diabetes direct medical costs \[[@CR3], [@CR4]\]. Indirect costs associated with diabetes, such as absenteeism from work and reduced productivity while at work, are also considerable \[[@CR3]\]. The most recent published cost data for Serbia are from 2007 \[[@CR5]\] and estimate that annual diabetes expenditures were 53,412.96 RSD (or 444.42 EUR[1](#Fn1){ref-type="fn"}) per patient. Indirect costs represented 10.39% of total costs, while anti-diabetes drugs and medical devices represented 44% (38.10% and 5.94%, respectively) and hospital and ambulatory costs the remaining 45%.

The aim of diabetes therapy is to keep blood glucose levels within recommended targets and ultimately limit the development of diabetes-related complications \[[@CR6], [@CR7]\]. All patients with type 1 diabetes (T1DM) require insulin. Current clinical guidance in Serbia recommends a basal-bolus regimen or for selected individuals continuous subcutaneous insulin infusion (CSII) by means of an external portable insulin pump \[[@CR8]\]. Type 2 diabetes (T2DM) is a progressive disease and treatment is intensified with disease progression. A significant proportion of patients with T2DM will eventually need insulin therapy to achieve optimal blood glucose targets \[[@CR8]\]. Insulin is the most effective method of reducing blood glucose concentrations; however, despite clear guidance, glycaemic control remains suboptimal (HbA~1c~ \> 7.0%) in a substantial number of patients \[[@CR9], [@CR10]\]. Key barriers to insulin therapy include fear and risk of hypoglycaemia, weight gain and restrictive treatment regimens \[[@CR11], [@CR12]\].

Insulin degludec (degludec) is a basal insulin analogue with a long duration of action and a distinct, slow absorption mechanism, which results in a flat and stable action profile \[[@CR13], [@CR14]\]. It has four times less day-to-day variability in glucose lowering effect than insulin glargine U100 (glargine U100) \[[@CR15]\]. Due to its long and stable action profile, degludec allows for flexibility of dosing time. On occasions when administration at the same time of day is not possible, patients can dose their insulin at any time of the day as long as there is a minimum of 8 h between doses \[[@CR16]--[@CR18]\].

The efficacy and safety of degludec have been evaluated in a large-scale clinical development programme. The degludec phase 3 clinical trial programme (BEGIN) included more than 9000 patients with T1DM and T2DM \[[@CR19]\]. Meta-analyses of the phase 3a clinical trials showed that degludec achieved equivalent reductions in HbA~1c~ with a lower risk of hypoglycaemia versus glargine U100 and at a significantly lower total daily insulin dose compared with glargine U100 in T1DM (12% lower) and T2DM basal oral therapy (10% lower) \[[@CR20], [@CR21]\]. Real-world studies confirm the observations from the clinical trials and support the effectiveness of degludec in clinical practice \[[@CR22], [@CR23]\].

Due to increasing constraints on healthcare budgets, it is important that new therapies represent good value for the money. Decision-making based on both clinical and economic evidence helps healthcare providers optimise resource use and care for patients with diabetes. Cost-effectiveness models assess the value of interventions by comparing the relative costs and outcomes. An economic analysis typically estimates the difference in cost between one healthcare intervention and an alternative, divided by the difference in health effects, which is termed an incremental cost-effectiveness ratio (ICER). A commonly used effectiveness measure in cost-effectiveness analyses is the quality-adjusted life year (QALY), which measures health as a combination of both duration and health-related quality of life \[[@CR24]\]. The incremental cost per additional QALY gained (cost/QALY) allows decision makers to compare across different disease areas to allocate healthcare resources for maximal economic and clinical benefits. A financial threshold is often set at which cost-effectiveness is accepted. In Serbia, there is no officially indicated threshold; however, the level of 3 × GDP per capita suggested by the World Health Organization (WHO) \[[@CR25]\] is accepted by the Serbian authorities.

The objective of this study was to evaluate the cost-effectiveness of degludec versus glargine U100 from the healthcare payer perspective in Serbia \[Serbian Health Insurance Fund (RFZO[2](#Fn2){ref-type="fn"})\].

Methods {#Sec2}
=======

Model Overview {#Sec3}
--------------

The type of cost-effectiveness analysis used was a cost-utility analysis. Degludec was compared with glargine U100 in three patient populations:T1DM using basal-bolus therapy (T1DM)T2DM using basal oral therapy (T2DM~BOT~)T2DM using basal-bolus therapy (T2DM~B/B~)

Glargine U100 was identified as the most appropriate comparator for the cost-utility analysis. Treatment guidelines in Serbia recommend NPH insulin as the first-line insulin treatment for T1DM and T2DM, with a basal insulin analogue considered if after 6 months on NPH there is persisting hypoglycaemia (\< 3.5 mmol/l). Thus, degludec should be considered where a basal insulin analogue is indicated.

The model was a simple, transparent, short-term (1-year time horizon) model developed in Microsoft Excel 2010 (Microsoft Corp., Redmond, WA, US) and has been previously published \[[@CR26]\]. The short-term model focuses on the impact of important aspects of insulin therapy, such as hypoglycaemia and dosing, and accommodates the treat-to-target trials required by the Food and Drug Administration (FDA) \[[@CR27]\]. In treat-to-target trials patients are treated to the same glycaemic target and no differences in HbA~1c~ are expected; thus, there is no rationale for long-term modelling based on HbA~1c~ differences.

Although cost-effectiveness was analysed in a 1-year setting and is based on data from 1-year clinical trials, the model can be replicated for subsequent years, and the outcomes represent the average annual cost-effectiveness in steady state. As the time horizon was 1-year, no discounting was applied.

The model calculated the costs associated with treatment (insulin, needles and SMBG test strips) and hypoglycaemic events (the cost of treating the event and the use of additional SMBG test strips associated with the event). Health-related quality of life (in the form of QALYs) was calculated by applying a disutility per hypoglycaemic event incurred (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Overview of cost-effectiveness model. *HCP* healthcare professional, *HRQoL* health-related quality of life, *hypo* hypoglycaemia, *ICER* incremental cost-effectiveness ratio, *IDeg* insulin degludec, *IGlar U100* insulin glargine, *QALY* quality-adjusted life year, *SMBG* self-monitored blood glucose

Perspective/Viewpoint {#Sec4}
---------------------

All costs were estimated from the healthcare payer perspective, RFZO. The threshold was set at 3 × GDP per capita, as although there are alternative approaches to thresholds for cost-effectiveness of interventions \[[@CR28]\], this is an internationally recognised level \[[@CR25]\] and is accepted by the Serbian authorities. According to the World Bank statistics for 2016, the GDP per capita in Serbia was 5348.30 USD. Using the exchange rate of 1 USD = 111.29 RSD, the threshold was set at the level of 1,785,642 RSD.

Data Used in the Model {#Sec5}
----------------------

### Cost Data {#Sec6}

All costs were estimated from the healthcare payer perspective, RFZO.

### Direct Treatment Costs {#Sec7}

Costs of insulin, needles and SMGB tests were based on official RFZO prices elicited in November 2017. Other costs of treatment (e.g. use of concomitant medication) or other costs resulting from treatment (e.g. long-term outcomes) were assumed to be equivalent in both treatment groups and were therefore not included.

### Cost of Hypoglycaemic Events {#Sec8}

Resource use associated with non-severe and severe hypoglycaemic events was derived from the clinical trial data. For non-severe events data were obtained from the patient-completed hypoglycaemia safety questionnaire, and for severe events data were obtained from the serious adverse events case reports \[[@CR29]\].

The use of additional SMBG tests in the week following a non-severe event was also based on the hypoglycaemia safety questionnaire. Data were not collected on the testing pattern following a severe event; therefore, it was conservatively assumed to be similar to a non-severe hypoglycaemic event.

For patients experiencing severe events it was assumed that all patients who were hospitalised used the ambulance service and that all patients experiencing severe events used glucagon to recover.

Patients suffering a hypoglycaemic event received the same treatment regardless of whether they were on degludec or glargine U100. Therefore, any difference in costs of hypoglycaemia between treatments was due to differences in rates of hypoglycaemia and not the cost per event.

The average costs of hypoglycaemic events are calculated by multiplying the unit cost of the services by the share of patients using that treatment/service (Table [1](#Tab1){ref-type="table"}). It was assumed that a non-severe event would be self-managed and not require any additional resource use; thus, costs relate only to additional SMBG testing.Table 1Total cost of an average severe/non-severe hypoglycaemic eventUnit cost (RSD)Utilisation per hypoglycaemic eventT1DM~B/B~T2DM~BOT~T2DM~B/B~SevereNon-severeSevereNon-severeSevereNon-severeGlucagon1695.70^a^1.00.01.00.01.00.0Ambulance3430.00^b^0.140.00.880.00.280.0Hospital3980.00^bc^0.140.00.880.00.280.0SMBG46.00^b^1.461.461.911.911.981.98TOTAL (RSD)**3357.4667.1611,806.7687.864975.9891.08**TOTAL RSD values are given in bold*B/B* basal-bolus, *BOT* basal oral therapy, *SMBG* self-measured blood glucose, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus, *RSD* Serbian dinar^a^RFZO listed price (November 2017)^b^HNF Rulebook on cost of services on the secondary/tertiary level indicators (July 2016)^c^Hospitalisation cost includes 2 days of hospital stay = 7960.00 RSD (<http://www.vma.mod.gov.rs/cenovnik-vma.pdf>)

Clinical Data {#Sec9}
-------------

### Insulin Dose {#Sec10}

The daily insulin dose for the degludec and glargine U100 treatment groups was based on the end of trial doses captured from the clinical trial data. The meta-analysis of insulin dose from the clinical trials was the source of the glargine U100 dose and degludec/glargine U100 dose ratio \[[@CR21]\]. The degludec dose was calculated using the dose ratio to allow for adjustment of covariate factors such as trial, treatment, antidiabetic therapy at screening, age, sex, region and baseline dose (Table [2](#Tab2){ref-type="table"}).Table 2Basal and bolus insulin useTreatment groupGlargine U100 (units/day)Dose ratio (degludec/glargine U100)Degludec (units/day)T1DM~B/B~, total dose0.88\*Basal insulin33.100.87\*28.80Bolus insulin35.000.88\*30.80T2DM~BOT~, total dose0.90\*Basal insulin51.700.90\*46.53Bolus insulinNot relevantNot relevantNot relevantT2DM~B/B~, total doseNSBasal insulin66.601.08\*71.93Bolus insulin72.70NS72.70*B/B* basal-bolus, *BOT* basal oral therapy, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus\**p* \< 0.05; *NS* non-significant; in the case of non-significant results, a relative rate of one was used in the calculation

### SMBG Testing {#Sec11}

It was assumed that one SMBG test was conducted with every main meal for regimens including bolus insulin (T1DM~B/B~, T2DM~B/B~). Three meals per day were assumed.

For SMBG tests related to basal insulin injections, the titration schedule recommended for use with glargine U100 \[[@CR30]\] was used to estimate SMBG utilisation for glargine U100. The algorithm recommends seven SMBG tests per week (the dose is adjusted every 3rd day based on the mean of the FPG results over three consecutive days) \[[@CR31]\].

Degludec enables patients to titrate, predict and monitor their blood glucose more efficiently \[[@CR13], [@CR14]\]. The recommended titration algorithm for degludec is once-weekly adjustment of dose based on the average of two SMBG measurements from the 2 preceding days for patients with T2DM \[[@CR32]\]. Thus, the utilisation of SMBG tests related to degludec was assumed to be two tests per week for patients with T2DM.

### Hypoglycaemia Event Rates {#Sec12}

Real-world hypoglycaemic event rates from a large-scale questionnaire-based study conducted in seven European countries \[[@CR33]\] were used as the baseline values for severe and non-severe hypoglycaemic events. These rates provide a better estimation of real-life event rates than those from clinical trials \[[@CR34]\], which can be biased in both the selection of patients and the treatment setting. For example, the clinical trials excluded patients with a history of severe hypoglycaemic episodes and anyone considered hypoglycaemia unaware \[[@CR34]--[@CR39]\]. The real-world rates were used as the base case event rates in the glargine U100 group (as this is the current treatment on the market); see Table [3](#Tab3){ref-type="table"}. Event rates for the degludec group (Table [3](#Tab3){ref-type="table"}) were calculated using the relative event rates taken from the meta-analysis of hypoglycaemia \[[@CR20], [@CR21]\], which were adjusted for trial, type of diabetes, treatment, anti-diabetic therapy at screening, sex and region as fixed factors and age as a continuous covariate. Only rate ratios with a documented statistically significant difference between the treatment arms were used.Table 3Calculation of hypoglycaemic event ratesT1DM~B/B~T2DM~BOT~T2DM~B/B~Non-severeSevereNon-severeSevereNon-severeSevereBaseline hypoglycaemia rate for glargine U100^a^91.00.720.30.1035.40.2Daytime/nocturnal split^b^DaytimeNocturnal--DaytimeNocturnal--DaytimeNocturnal--78%22%68%32%78%22%Total events per patient per year for glargine U10070.9820.020.713.806.500.1027.617.790.20Degludec/glargine U100 hypoglycaemic event rate ratioNS0.83\*NSNS0.64\*0.14\*0.83\*0.75\*NSCalculated degludec hypoglycaemic event rate70.9816.620.713.804.100.0122.925.840.20*B/B* basal-bolus, *BOT* basal oral therapy, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus\**p* \< 0.05; NS, non-significant; in the case of non-significant results, a relative rate of one was used in the calculation^a^Taken from Östenson et al. \[[@CR33]\]^b^Proportion of daytime nocturnal events for glargine U100 taken from Östenson et al. \[[@CR33]\]

### Compliance with Ethics Guidelines {#Sec13}

This article does not contain any studies with human participants or animals performed by any of the authors.

Utility Data {#Sec14}
------------

QALYs were calculated by subtracting a disutility \[[@CR40]\] per hypoglycaemic event experienced from the baseline health utility. Disutilities associated with hypoglycaemic events were obtained from a large-scale TTO study \[[@CR40]\], which reported a disutility of 0.0565 for a severe event (with no significant difference between daytime and nocturnal severe events) and disutilities of 0.0041 and 0.0067 for non-severe daytime and non-severe nocturnal events, respectively (a significant difference in utility was demonstrated for nocturnal vs. daytime non-severe events) \[[@CR40]\]. The disutility per hypoglycaemic event was multiplied by the number of events observed in each treatment group.

In addition, the analysis included an estimate of the utility benefit for the option of flexible dosing time with degludec. Boye et al. \[[@CR41]\] reported a utility benefit of 0.006 associated with dosing flexibility; therefore, for degludec an extra utility gain of + 0.006 was applied to the QALY benefit.

Sensitivity Analyses {#Sec15}
--------------------

One-way and probabilistic sensitivity analyses were conducted to assess the impact of varying key assumptions and outcomes used in the base case analysis (Table [4](#Tab4){ref-type="table"}).Table 4Description of sensitivity analyses conductedTime horizonIn the base case analysis the time horizon was 1 year. Sensitivity analysis increased the time horizon to 5 yearsHypoglycaemia ratesThe base case rate of hypoglycaemia was taken from the published literature as it is believed that this provides a more realistic event rate. Additional published event rates, and the actual reported rates from the clinical trial programme, were investigated in sensitivity analysesSMBG costsSMBG costs were varied ± 20%Hypoglycaemia costsA sensitivity analysis was conducted where the cost of a non-severe hypoglycaemic event included the cost of one visit to the GP following the event (192.11 RSD)\
For severe hypoglycaemic events costs were varied ± 20%DosingA sensitivity analysis was conducted with an assumption of equal doses for degludec and glargine U100Injection frequencyFor some patients, current basal insulins need to be taken twice daily to ensure optimal control. The effect of using twice as many needles for the basal injections in the glargine U100 group was exploredSMBG tests per weekFor degludec, the long duration of action and stable action profile \[[@CR13], [@CR14]\] mean that patients are able to titrate, predict and monitor their blood glucose more efficiently. The recommended titration algorithm for degludec is once-weekly adjustment of dose based on the average of two SMBG measurements from the 2 preceding days for patients with T2DM (98). The number of SMBG tests for basal titration with degludec was varied between 2 and 7 (T2DM~BOT~) and between 23 and 28 (T2DM~B/B~)Additional SMBG tests after non-severe eventsIn the base case analysis the number of additional SMBG tests following a non-severe event was taken from the clinical trial data. A sensitivity analysis was conducted, which used a published source that reported 6.2 additional tests following a non-severe event \[[@CR42]\] and another analysis that assumed no additional testsFlexible dosing utilityA number of sensitivity analyses were conducted around this assumption: one where only 50% of patients were assumed to receive the benefit of flexible dosing, one that used an alternative published utility value (0.013 \[[@CR43]\]) and one that assumed no utility from flexible dosingProbabilistic sensitivity analysis (PSA)PSA used the standard errors and appropriate distributions of the parameters. The distributions were assumed to be either normal or lognormal and each individual parameter was selected independently. The probabilistic sensitivity analyses were run with 1000 iterations. In the primary analysis for each of the groups---the standard error was only applied to differences that were statistically significant (i.e. if there was no statistical significance proven---then the rate ratio was set to 1 (assumed equivalent) and the SE was set to 0 (so as not to introduce random uncertainty)

Results {#Sec16}
=======

Costs {#Sec17}
-----

In T1DM, total costs are estimated at 185,627.84 RSD per patient per year in the degludec group and 173,637.52 per patient per year in the glargine U100 group, with the majority representing pharmacy costs. The total cost per patient per year is 11,990.32 RSD higher in the degludec group than in the glargine U100 group (6.9% higher costs), largely because of the increase in insulin costs. The costs of hypoglycaemic events are similar for degludec and glargine U100 since only the non-severe nocturnal events showed a statistically significant difference between the two treatments, and the severe and daytime events were unchanged.

In T2DM~BOT~, the total cost per patient per year in the degludec group (101,270.97 RSD) is 15,042.55 RSD (17.4%) higher than in the glargine U100 group (86,228.42 RSD per patient per year). The difference in cost is due to the increased cost for insulin and the lower costs of SMBG testing and non-severe nocturnal and severe hypoglycaemic events in the degludec group. Lower costs of hypoglycaemia are driven by the significant reduction in the number of severe hypoglycaemic events with degludec vs. glargine U100 in this patient group.

In T2DM~B/B~, the total cost per patient per year in the degludec group (285,584.00 RSD) is 45,912.88 (19.2%) higher than in the glargine U100 group (239,671.12 RSD per patient per year), caused primarily by a higher spend for insulin partly offset against a lower spend on SMBG and lower costs of non-severe daytime and nocturnal hypoglycaemia. The higher incremental cost for this group is driven mainly by the slightly higher dose of basal insulin required in the degludec arm of the clinical trial. In the T2DM~B/B~ clinical trial \[[@CR14]\], high insulin doses were observed in both the degludec and glargine U100 treatment arms. The high doses observed in the trial are not expected to be representative of a real-world setting for patients initiating a basal-bolus regimen as the trial mainly recruited patients who were already uncontrolled on an intensive basal-bolus regimen or uncontrolled on a pre-mixed insulin regimen. In a recent real-world study of degludec, the daily basal and bolus insulin doses in patients with T2DM (75% on a basal-bolus regimen) were considerably lower than those in the clinical trial \[[@CR23]\].

Average total costs for the three treatment groups are presented in Table [5](#Tab5){ref-type="table"}.Table 5Results: average total costs (RSD) per patient per year and incremental cost-effectivenessT1DMT2DM~BOT~T2DM~B/B~Cost, degludec (RSD)185,627.84101,270.97285,584.00Cost, glargine U100 (RSD)173,637.5286,228.42239,671.12Δ costs11,990.3215,042.5545,912.88Δ QALYs0.02870.02690.0383ICER (RSD/QALY)417,586.27558,811.001,200,140.55

Incremental Cost-Effectiveness {#Sec18}
------------------------------

Degludec is a highly cost-effective treatment option versus glargine U100 in patients with T1DM as part of a basal-bolus insulin regimen with an estimated ICER of 417,586.27 RSD/QALY gained. The result is primarily driven by the significantly lower dose required, QALY gains due to significantly fewer non-severe nocturnal hypoglycaemic events versus glargine U100 and the opportunity to use flexible dosing when needed. This result falls well beneath the cost-effectiveness threshold in Serbia of 1,785,642 RSD/QALY gained.

In T2DM~BOT~ degludec is also highly cost-effective (558,811.00 RSD/QALY gained), driven by cost savings from a significantly lower dose, a significant reduction in severe hypoglycaemia and the potential for once-weekly SMBG testing. Due to the significantly fewer nocturnal and severe hypoglycaemic events in this group and the opportunity to use a flexible dosing time when needed, degludec is associated with a QALY gain versus glargine U100.

In the T2DM~B/B~ setting, degludec is cost-effective with an ICER of 1,200,140.55 RSD/QALY gained, which falls below commonly accepted cost-effectiveness threshold. Degludec is associated with significantly fewer non-severe daytime and nocturnal events, which results in a QALY gain versus glargine U100.

Sensitivity Analysis {#Sec19}
--------------------

Extensive sensitivity analyses demonstrate that the results are robust and largely insensitive to changes in input parameters (results presented in supplementary table).

Key parameters that influenced the ICER values were hypoglycaemia rates (T1DM, T2DM~BOT~, T2DM~B/B~), insulin doses (T1DM, T2DM~BOT~) and the number of SMBG tests used weekly by patients (T2DM~BOT~, T2DM~B/B~).

For T1DM, the ICER remains below the cost-effectiveness threshold in all scenarios tested in one-way sensitivity analyses. ICERs range between 297,452 RSD/QALY gained and 1,179,023 RSD/QALY gained. Rates of non-severe hypoglycaemia are influential on the ICER in this group. When the annual number of non-severe daytime events is reduced to 36.16 using data from Donnelly et al. \[[@CR34]\], the ICER increases to 997,799 RSD/QALY gained. Conversely, when the annual number of non-severe nocturnal events is increased to 20.80 using data from Ericsson et al. \[[@CR44]\], the ICER is reduced to 404,428 RSD/QALY gained. The insulin dose ratio also has an impact on the ICER, but even under an extreme assumption of equal dosing of basal insulin, degludec remains highly cost-effective (720,507 RSD/QALY gained). If the utility gain from flexibility is excluded, the ICER is still within commonly accepted thresholds (527,896 RSD/QALY gained).

Similarly for T2DM~BOT~, the favourable cost-effectiveness results are invariant to changes in most of the input parameters. ICERs range between 294,932 and 1,955,556 RSD/QALY gained. The number of SMBG tests per week is influential on the ICER in this setting, but degludec is still cost-effective (1,004,600 RSD/QALY gained) even under the strict assumption of no reductions in SMBG testing in the degludec group. Insulin dose ratio and utility gain from flexibility also have an impact on the results, but ICERs fall below the commonly accepted threshold even with extreme assumptions (919,928 and 719,091 RSD/QALY gained respectively). Varying the rates of hypoglycaemia has an impact on the ICER in this group reflecting the large benefits in terms of reduced hypoglycaemia with degludec versus glargine U100. Drawing on higher event rates for non-severe events generates highly cost-effective results for degludec versus glargine U100; conversely, using lower event rates for severe hypoglycaemic events, e.g. from Ratner \[[@CR20]\], increases the ICER to 1,955,556.24 RSD/QALY gained, which is just above the commonly accepted threshold.

For T2DM~B/B~ the parameter that has the most influence on the ICER is the rate of hypoglycaemia. Varying the rate of non-severe hypoglycaemia has an impact on the ICER in this group due to the significant reduction of non-severe events with degludec versus glargine U100. ICERs range between 980,305 and 3,636,384 RSD/QALY gained, with low rates of non-severe hypoglycaemia generating the higher ICERs. In all other scenarios analysed the ICERs are below the commonly accepted threshold (range 938,549--1,513,491 RSD/QALY gained), indicating that degludec is a cost-effective therapeutic option in this group.

Probabilistic Sensitivity Analysis {#Sec20}
----------------------------------

To capture the uncertainty of the results caused by statistical uncertainty with respect to the parameter inputs, probabilistic sensitivity analysis has been conducted. The probabilistic sensitivity analyses have each been run with 1000 iterations.

The cost-effectiveness acceptability curves show that at a willingness-to-pay threshold of 2,048,112 RSD/QALY gained, the probability that degludec is cost-effective relative to glargine U100 is 77.5, 97.3 and 85.7% for T1DM, T2DM~BOT~ and T2DM~B/B~, respectively (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Probabilistic sensitivity analysis---cost-effectiveness acceptability curves

Discussion {#Sec21}
==========

There are limited data on the cost-effectiveness of treatments for diabetes in Serbia. With an increasing number of insulin formulations available, economic as well as clinical evidence is essential for healthcare providers to maximise healthcare with constrained budgets.

This simple, short-term economic evaluation demonstrates that degludec is likely to be considered highly cost-effective compared with glargine U100 for people with T1DM and T2DM in Serbia. All ICERs fall below the commonly accepted thresholds for cost-effectiveness in Serbia.

In all three patient groups, insulin costs are higher with degludec than with glargine U100, but these costs are partially offset by savings from a lower daily insulin dose in T1DM and T2DM~BOT~, a reduction in hypoglycaemic events in all three patient groups and reduced costs of SMBG testing in the T2DM groups, with degludec versus glargine U100. For degludec, the longer half-life and the corresponding long flat insulin profile in steady state \[[@CR15]\] and lower variability over the day compared with glargine U100 \[[@CR45]\] mean that patients are able to titrate, predict and monitor their blood glucose more efficiently. Consequently, degludec can be monitored with less frequent SMBG testing in patients with T2DM. The titration algorithm for degludec is once-weekly adjustment of dose based on the average of two SMBG measurements from the 2 preceding days for patients with T2DM \[[@CR46]\]. The concept of fewer SMBG tests per week is supported by a phase 3b trial, which examined different scenarios of SMBG testing in patients with T2DM. The trial demonstrated that degludec was effective and well tolerated using only one SMBG test per week to titrate the insulin dose compared with titration based on three consecutive pre-breakfast SMBG values in patients with T2DM \[[@CR47]\]. No statistically significant differences in HbA~1c~, body weight, hypoglycaemia or any other safety parameters were observed between the two titration algorithms \[[@CR47]\].

An important aspect to consider, especially for chronic diseases such as diabetes mellitus, is the quality of life of patients. With degludec higher gains in health-related quality of life (HRQoL) were observed \[[@CR48]\]. Incremental QALY gains with degludec versus glargine U100 in all three groups are associated with the reduction in hypoglycaemic events and the opportunity to use flexible dosing when needed. The current analysis included an estimate of the utility benefit of a flexible dosing time with degludec. This additional utility was not captured in the clinical studies and therefore a utility gain of 0.006 for degludec related to flexible dosing was assumed based on the study by Boye et al. \[[@CR41]\]. This can be seen as a conservative estimate as a large time trade-off study demonstrated that flexible once-daily injection was associated with a 0.016 higher utility versus a fixed time of injection \[[@CR43]\].

Extensive sensitivity analyses show that the results are robust and invariant to changes in most of the input parameters. In all three patients groups the ICER remained below the threshold of 1,785,642 RSD in all scenarios tested, except when low rates of non-severe hypoglycaemia were applied in the T2DM~B/B~ setting and low rates of severe hypoglycaemia applied in the T2DM~BOT~ setting. PSA shows that there is a high probability that degludec will be cost-effective versus glargine U100 in all three patient groups.

Hypoglycaemia can have a major impact on patients' lives affecting employment, driving, relationships, travel and leisure activities. Severe episodes can result in serious clinical sequelae such as physical (e.g. fractures, head injuries), neurological (e.g. convulsions/seizures, paralysis, coma) and cardiac (e.g. arrhythmia, cardiac failure) morbidity, as well as death in some extreme cases \[[@CR49], [@CR50]\]. Furthermore, recurrent episodes, whether severe or non-severe, can lead to the development of impaired awareness of hypoglycaemia; this can be problematic as it means that patients are less able to recognise their symptoms and take remedial action. A recent non-interventional, prospective-cohort survey conducted across 2004 sites in 24 countries, including Serbia, investigated the prevalence of hypoglycaemia \[[@CR51]\]. The study included 27,585 patients with insulin-treated diabetes and reported a higher frequency of hypoglycaemia than previously reported, with marked variation across geographic regions. Overall rates of hypoglycaemia in Eastern Europe were 66.9 events/person/year for T1DM and 23.7 events/person/year for T2DM, with the highest rates in T2DM observed in Russia and Eastern Europe. Data from this study also show that hypoglycaemia has a major impact on patients and their behaviour \[[@CR52]\]. In Eastern Europe 51.7% T1DM and 40.6% T2DM patients reduced their insulin dose in response to hypoglycaemia, which could compromise glycaemic control, and high proportions increased blood glucose monitoring (75.5% T1DM and 71.9% T2DM).

Hypoglycaemia and the fear of hypoglycaemia act as barriers to timely initiation and intensification of insulin and remain the major limiting factors for achieving target levels of glucose control in insulin-treated patients with diabetes \[[@CR53], [@CR54]\]. Poor glycaemic control is associated with serious long-term complications, including cardiovascular disease, renal disease, retinopathy, amputation, depression and neuropathy \[[@CR55], [@CR56]\].

Due to its distinct pharmacological profile degludec is associated with lower rates of hypoglycaemia. In phase 3a clinical trials degludec showed equivalent reductions in HbA~1c~ with a significantly lower rate of hypoglycaemia versus glargine U100 \[[@CR20], [@CR21]\]. Degludec was associated with a 17% lower rate of nocturnal non-severe hypoglycaemia in T1DM \[[@CR21]\], an 86% lower rate of severe hypoglycaemia and a 36% lower rate of nocturnal non-severe hypoglycaemia in T2DM~BOT~ \[[@CR20], [@CR21]\], as well as a 25% lower rate of nocturnal non-severe hypoglycaemia and 17% lower rate of daytime non-severe hypoglycaemia in T2DM~B/B~ \[[@CR21]\], compared with glargine U100. Two phase 3b studies, SWITCH 1 and SWITCH 2, investigated the efficacy and safety of degludec in patients with T1DM and T2DM with an increased risk of hypoglycaemia \[[@CR57], [@CR58]\]. In these studies equivalent reductions in HbA~1c~ were achieved with degludec with a lower total daily insulin dose at end of trial and with a lower risk of hypoglycaemic episodes versus glargine U100 \[[@CR57], [@CR58]\]. The hypoglycaemia benefits of degludec have also been reported in real-world clinical practice, with reductions of up to 90% observed in patients switching to degludec because of problems with hypoglycaemia on glargine U100 or insulin detemir \[[@CR22]\].

A limitation of the current economic analysis, common to modelling studies, is the generalisability of clinical trial data to routine clinical practice. The clinical trials included in the meta-analyses used a treat-to-target approach, and insulin was titrated to a predetermined glycaemic target. In contrast, optimal glycaemic control may not be achieved in clinical practice because of non-adherence or poor clinic attendance. However, the sensitivity analyses indicate that the conclusions are robust. Furthermore, real-world studies confirm the observations from the clinical trials and support the effectiveness of degludec in clinical practice. The EUropean TREsiba AudiT (EU_TREAT) is a multinational observational study in the general diabetes population in routine care to assess the effectiveness of degludec \[[@CR23]\]. A total of 2550 patients were included in the study (T1DM = 1717, T2DM = 833), and results demonstrated that switching to degludec from other basal insulins significantly improved glycaemic control and reduced the risk of overall, nocturnal and severe hypoglycaemia \[[@CR23]\].

The real-world study used for baseline rates of hypoglycaemia \[[@CR33]\] was based upon patient recall of hypoglycaemic events and the interpretation of symptoms may be open to bias. The study was designed to maximise the optimum recall period; however, symptoms of hypoglycaemia can be incorrectly interpreted. The uncertainty around hypoglycaemia rates was explored in a number of sensitivity analyses, and whilst hypoglycaemia rates are a key driver of cost-effectiveness outcomes the conclusion that degludec is cost-effective is robust to applying alternative values.

An advantage of the modelling approach used for this economic analysis is its simplicity. This short-term approach focuses on the impact of important aspects of insulin therapy such as hypoglycaemia and dosing and enables economic analysis of new insulins that have been evaluated in treat-to-target trials. This model has been previously used to evaluate the cost-effectiveness of degludec versus glargine U100 in patients with T1DM and T2DM \[[@CR44], [@CR59]--[@CR61]\]. An analysis from the UK perspective found that degludec was dominant to glargine U100 in the T1DM and T2DM~BOT~ populations and highly cost-effective in the T2DM~B/B~ population \[[@CR26]\]. Similarly, in a Swedish setting degludec was cost-effective versus glargine U100 in all three patient groups \[[@CR44]\]. In both cases, results are consistent with those observed in this study.

Conclusion {#Sec22}
==========

This short-term economic evaluation indicates that degludec is a cost-effective alternative to glargine U100 for patients with T1DM and T2DM in Serbia. Degludec may particularly benefit those suffering from hypoglycaemia or where the patient would benefit from the additional flexibility.
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